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Background: In resource-limited settings, monitoring and evaluation (M&E) of antiretroviral treatment (ART) programs
often relies on aggregated facility-level data. Such data are limited, however, because of the potential for ecological
bias, although collecting detailed patient-level data is often prohibitively expensive. To resolve this dilemma, we
propose the use of the two-phase design. Specifically, when the outcome of interest is binary, the two-phase design
provides a framework within which researchers can resolve ecological bias through the collection of patient-level data
on a sub-sample of individuals while making use of the routinely collected aggregated data to obtain potentially
substantial efficiency gains.
Methods: Between 2005–2007, the Malawian Ministry of Health conducted a one-time cross-sectional survey of 82,887
patients registered at 189 ART clinics. Using these patient data, an aggregated dataset is constructed to mimic the type
of data that it routinely available. A hypothetical study of risk factors for patient outcomes at 6 months post-registration
is considered. Analyses are conducted based on: (i) complete patient-level data; (ii) aggregated data; (iii) a hypothetical
case–control study; (iv) a hypothetical two-phase study stratified on clinic type; and, (v) a hypothetical two-phase study
stratified on clinic type and registration year. A simulation study is conducted to compare statistical power to detect an
interaction between clinic type and year of registration across the designs.
Results: Analyses and conclusions based solely on aggregated data may suffer from ecological bias. Collecting and
analyzing patient data using either a case–control or two-phase design resolves ecological bias to provide valid
conclusions. To detect the interaction between clinic type and year of registration, the case–control design would
require a prohibitively large sample size. In contrast, a two-phase design that stratifies on clinic and year of
registration achieves greater than 85% power with as few as 1,000 patient samples.
Conclusions: Two-phase designs have the potential to augment current M&E efforts in resource-limited settings
by providing a framework for the collection and analysis of patient data. The design is cost-efficient in the sense
that it often requires far fewer patients to be sampled when compared to standard designs.
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The long-term success of national antiretroviral treatment
(ART) programs relies on accurate and timely systems for
monitoring and evaluation (M&E). Data from such sys-
tems are used for program planning, management of the
commodity supply chain, to identify and address emerging
implementation or clinical problems, and to facilitate
epidemiologic analysis and operations research [1]. With
these purposes in mind, M&E systems would ideally rec-
ord detailed patient-level data on demographic character-
istics, medical history, clinical information including
virologic and CD4 counts at the time of ART initiation,
and outcomes. Toward this ideal, a number of small-scale
programs have been successful in establishing infrastruc-
tures that routinely collect electronic patient-level data
[2-6] and, armed with patient-level data, researchers have
been able to address a range of important questions
regarding program retention, treatment adherence, drug
resistance and mortality [7-13].
Unfortunately, however, implementing comprehensive
data collection infrastructures on a national scale in
resource-limited settings is prohibitively expensive [14].
In response, the World Health Organization (WHO)
public-health approach advocates a simplified strategy
for M&E that relies primarily on aggregated, facility-
level data [1,3,15]. While these aggregated data represent
a critical resource [16-18], they lack the detail and speci-
ficity of patient-level data and are therefore limited. In
particular, investigations of associations for patient-level
outcomes based on aggregated data may suffer from
ecological bias [19,20] and, in the worst-case scenario,
the ecological fallacy where conclusions based on aggre-
gated data are different than those that would have been
drawn had a patient-level analysis been performed [21].
In general, the only reliable approach to overcoming
ecological bias is to collect and analyze patient-level data
[22]. Fortunately, researchers have at their disposal a
broad range of study designs on which to base data
collection for a sub-sample of patients. When the out-
come is binary, for example, the case–control design is
well-known to be efficient relative to random sampling
[23]. The case–control design fails, however, to make
use of any information other than outcome status. As an
alternative we propose strategies for cost-efficient M&E
of patient-level outcomes for national ART programs in
resource-limited settings based on the two-phase study
design [24-27]. As we elaborate upon, two-phase designs
provide a framework within which routinely collected
aggregated data can be used to identify sub-samples of
patients on whom detailed information is collected. To
illustrate the design, in terms of both resolving ecological
bias and increased statistical power relative to the case–
control design, we use data from a cross-sectional survey
on the national ART program in Malawi.Methods
The Malawian national ART program
The national ART program in Malawi coordinates care
at over 650 clinic sites across the country [28]. Every
three months, the Ministry of Health conducts supervi-
sion visits to each clinic. During each supervision visit
all patients who were newly registered in the previous
three months are said to belong to a specific ‘quarterly-
clinic cohort’ [28,29]. For all patients in the quarterly-
clinic cohort, information recorded on paper-based master
cards and stored at the clinic on all patients in each
quarterly-clinic cohort is categorized and aggregated. This
results in a single record, specific to the entire quarterly-
clinic cohort, that includes the number of males/females,
the number of adults/children, and the number of patients
in different clinical stages. Note, the single record does
not include information on the cross-classification of
these variables; it does not, example, include separate
counts for the number of female adults and male adults.
For other quarterly-clinic cohorts at the clinic (i.e. patients
registered in previous 3-month periods), aggregated
follow-up information such as the total number of
retained registrants, the total number of patients who
remain adherent to ART, and totals regarding side ef-
fects. Finally, ‘cumulative outcomes’ are classified and
tallied, giving totals based on the status of patients at
their most recent visit before the end of the quarter
evaluated. After completing this aggregation process,
all quarterly-clinic cohort-specific records are returned
to the Ministry of Health, entered into an electronic
database and prepared for analysis [30,31].
Between 04/2008 and 05/2009 the Malawian Ministry
of Health also conducted a one-time, cross-sectional
survey of their national ART program. For each program
registrant baseline demographic characteristics (age,
gender and WHO stage) were recorded, as well as treat-
ment information (date of ART initiation and current
regimen) and information on the clinic (location and
clinic type). In addition, the patient’s status at the time
of the survey was also recorded. This information was
then used to create a binary outcome of ‘status at six
months post-registration’: stopped treatment, lost to
follow-up and death within 180 days were considered
‘negative’; transferred-out and alive and on-treatment
were considered ‘non-negative’.
Ethics statement
Measures are in place in all ART facilities to ensure
patient confidentiality, consent for HIV testing, and
counseling and support for those who receive a positive
HIV test result. Studies using data collected routinely
within the context of monitoring and evaluation, such
as ART registers, do not require formal approval by the
Malawi National Health Science Research Committee.
Table 1 Patient outcomes at six months, by patient and
clinic characteristics as well as by year of registration
Status at six months Rate, %
Non-negativea Negativeb
Overall 66,746 16,141 19.5
Age, years
16-25 7,116 2,130 23.0
26-35 26,460 6,575 19.9
36-45 21,078 4,756 18.4
46-55 8,835 1,888 17.6
56-65 2,785 656 19.1
>65 472 136 22.4
Gender
Male 25,150 7,172 22.2
Female 41,596 8,969 17.7
WHO stage
1/2 4,418 314 6.6
3/4 62,328 15,827 20.3
Region
Central/North 27,662 7,269 20.8
South 39,084 8,872 18.5
Registration year
2005 12,238 3,514 22.3
2006 23,893 6,181 20.6
2007 30,615 6,446 17.4
Clinic type
Public 64,651 15,839 19.7
Private 2,095 302 12.6
aNon-negative = transferred-out or alive and on-treatment.
bNegative = stopping treatment, lost to follow-up or death.
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manuscript was determined to be ‘Not Human Subjects
Research’ by both the Harvard School of Public Health
and the Harvard School of Medicine.
The potential for ecological bias
As indicated above, the reliance of current systems for
M&E on aggregated facility-level data renders analyses
open to potential ecological bias. Prior to detailing the
use of two-phase designs in the M&E setting, we first
motivate the use of the design by illustrating ecological
bias in a hypothetical study of the association between
clinic type (private vs. public) and outcomes six-month
post-registration in the program. Specifically, we con-
structed and analyzed an (artificially) aggregated dataset
using the survey data and compared the results to a
“gold-standard” analysis based on the patient-level data.
For the latter we fit a logistic regression model to adults
(≥16 years) who registered between 2005 and 2007,
started ART at registration and had at least six months
of follow-up. For simplicity, and to focus the analysis on
illustrating ecological bias, we further restricted to pa-
tients with non-missing baseline demographic informa-
tion, yielding an overall sample size of N = 82,877. To
provide some adjustment for case-mix differences be-
tween patients registered at private and public clinics, we
included in the model the following covariates: age, gen-
der, WHO stage at registration and region. Finally, an
interaction between clinic type and year of registration
was included to investigate whether or not differences
between public and private clinics changed over time.
Towards mimicking the current systems in Malawi we
first assigned each of the N = 82,877 patients to a
quarterly-clinic cohort on the basis of their date and loca-
tion of registration. For each of the resulting N* = 1,518
quarterly-clinic cohorts we computed a series of aggre-
gated counts/measures including: the total number of reg-
istrants, the average age, the number and percent female,
the number and percent with WHO stage 3/4 at registra-
tion and number and percent with a negative outcome
status. To analyze the aggregated quarterly-clinic cohort
dataset we fit a logistic regression model with the num-
ber of patients with a negative six-month status in the
quarterly-clinic cohort as a binomial outcome. The ap-
proach to adjustment followed that of the complete
patient-level data analysis and included the following
group-level covariates: mean age, percent female, an
indicator of whether or not the percent WHO stage 3/4
was ≤/> 90%, and region. A main effect for clinic type was
included, along with interaction terms with year of regis-
tration. To accommodate potential overdispersion, and
ensure valid 95% confidence intervals, we used quasi-
likelihood for estimation and inference [32].Two-phase designs for M&E
In theory, collecting complete patient-level data on a na-
tional scale and on a routine basis in Malawi is possible;
as mentioned, patient-level data is recorded on paper
master cards and stored at each clinic. In practice, how-
ever, collecting these data on all registrants of the
national ART program is not feasible. As an alternative
to attempting to collect patient data on all registrants is
to do so on a select sub-sample of patients. In the
context of a rare binary outcome, the case–control de-
sign is well-known to provide substantial efficiency gains
relative to simple random sampling [23]. In Malawi, a
case–control study could easily be implemented by
stratifying the registrant population (i.e. the N = 82,887
patients) on the known number of cases and non-cases
(N1 = 16,141 and N0 = 66,746; see Table 1), selecting a
random sub-sample from each outcome-specific strata
and transferring data for the selected patients from their
master cards into an electronic format for analysis.
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control design can be used to resolve ecological bias, it
makes no use of the routinely collected aggregated
quarterly-clinic cohort data. Two-phase designs provide
a framework for using these data [27]. In the Malawian
context, phase I would correspond to a stratification of
the entire population on the basis of outcome status (as
in a case–control design) and the known aggregated
quarterly-clinic cohort data. Table 2 provides six possible
phase I stratifications for the N = 82,877 patients.
Design #1 exploits the fact that whether a clinic is pri-
vate or public is common to all patients in the
quarterly-clinic cohort. Consequently, it is possible to
cross-classify all patients (across all N* = 1,518) by out-
come status and type of clinic. Similarly, since each
quarterly-clinic cohort is specific to 2005, 2006 or
2007 it if possible to further cross-classify the counts
by year of registration as in Design #2. In Design #3,
the cross-classification exploits the fact that all pa-
tients in a quarterly-clinic cohort “share” the common
prevalence of WHO stage 1 or 2, even though the
values vary within the quarterly-clinic cohort. SimilarlyTable 2 Six possible phase I stratification schemes that use re
current M&E systems in Malawi
Design #1 Private clinic
No Yes
Non-negative status 64,651 2,095
Negative status 15,839 302
Design #2 Year of registration/Private clinic
2005/No 2005/Yes
Non-negative status 11,991 247
Negative status 3,492 22
Design #3 Percent WHO stage 1 or 2
≤5% >5%
Non-negative status 50,570 16,176
Negative status 13,191 2,950
Design #4 Average age, years
≤35 36-40
Non-negative status 12,954 51,959
Negative status 3,570 12,239
Design #5 Percent female
0% 1-40%
Non-negative status 189 3,360
Negative status 20 630
Design #6 Percent WHO stage 1 or 2/Private clinic
≤5%/No >5%/No
Non-negative status 49,160 15,491
Negative status 12,796 2,863in Designs #4 and Designs #5 for the “shared” average
age and percent female in the quarterly-clinic cohort.
Finally, Design #6 further illustrates the potential for
combining two group-level covariates to more finely
stratify the phase I sample.
Focusing on Designs #1 and #2 for the remainder of
this paper, given a phase I stratification scheme, sub-
samples of patients are chosen from each of the phase I
strata and, as in a case–control design, detailed patient
data is retrospectively ascertained. These data are col-
lectively referred to as the phase II data. In practice, the
number of patients sampled at phase II is typically fixed
and one must decide how to allocate those resources
across the phase I strata. One straightforward strategy is
to adopt a balanced design that allocates them equally.
For Design #1, given resources to collect a sub-sample
of n = 5,000, a balanced design would collect 1,250 pa-
tients from each phase I strata. Since only 302 patients
were registered at private clinics and had a negative out-
come, all of these patients would be sampled; the
remaining 2,198 ‘cases’ would then be sampled from
public clinics. Similarly, for a fixed phase II sample sizeadily-available group-level information collected by the
2006/No 2006/Yes 2007/No 2007/Yes
22,887 1,006 29,773 842




41-50% 51-60% 60-99% 100%
4,766 19,255 38,949 227




Table 3 Characteristics of N = 82,877 patients and the
corresponding N* = 1,518 quarterly-clinic cohorts, from a
cross-sectional survey conducted in Malawi between
04/2008-05/2009
Patients Quarterly-clinic cohorts
N % N* %
Total 82,887 Total 1,518
Age, years Average age, years
16-25 9,246 11.2 ≤30 62 4.1
26-35 33,035 39.9 31-35 344 22.7
36-45 25,834 31.2 36-40 921 60.7
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from each of the 12 phase I strata in Design #2. As in
Design #1, some strata do not contain sufficient patients
and the remainder could be drawn from the other (out-
come-specific) strata.
Given data from a two-phase design, analysts can use
any of a number of different approaches to estimation
and inference for an underlying logistic regression
model, including weighted likelihood, pseudo-likelihood
and maximum likelihood [33,34]. Each of these approaches
have been implemented and are currently available in the
osDesign package for R [35].46-55 10,723 12.9 41-45 137 9.0
56-65 3,441 4.2 46-50 31 2.0
>65 608 0.7 >50 23 1.5
Gender Percent female
Male 32,322 39.0 0% 114 7.5





WHO stage Percent WHO stage 3/4
1/2 4,732 5.7 ≤90% 255 16.8
3/4 78,155 94.3 >90% 1,263 83.2
Region Region
Central/North 34,931 42.1 Central/North 720 47.4
South 47,956 57.9 South 798 52.6
Year of registration Year of registration
2005 15,752 19.0 2005 334 22.0
2006 30,074 36.3 2006 560 36.9
2007 37,061 44.7 2007 624 41.1A simulation to investigate statistical power
To further illustrate the potential and benefit of the two-
phase design, we performed a series of simulations to in-
vestigate statistical power. Specifically, we generated 1,000
simulated datasets each of size N = 82,887 and with the
same covariate distribution as the survey data. Outcomes
were generated as Bernoulli random draws with a patients’
probability determined by the “gold-standard” logistic re-
gression analysis of the patient-level data in the survey.
For each dataset, and for a range of sub-sample sample
sizes, we simulated a case–control study and the two
two-phase designs described above. Note, since the out-
comes are simulated, they vary from dataset to dataset;
as such, the observed actual phase I stratification varied
from dataset to dataset. For each dataset, we then esti-
mated the regression parameters from the underlying lo-
gistic regression model using maximum likelihood and
evaluated whether or not the interaction terms were sta-
tistically different from zero (based on a Wald test with
2 degrees of freedom). Statistical power was evaluated as
the proportion of instances in which the null hypothesis
of no interaction was rejected.Clinic type Clinic type
Public 80,490 97.1 Public 1,217 80.2
Private 2,397 2.9 Private 301 19.8
Results
Table 3 provides a summary of the data observed in the
survey; the left-hand side summaries patient-level char-
acteristics of the N = 82,877 patients; the right-hand
summaries the group-level data for the N* = 1,518
quarterly-clinic cohorts. From the left-hand side, we see
that 9,246 of the N = 82,887 patients (11.2%) were aged
16–25 years, 4,049 (4.9%) were older than 55 years,
50,565 (61%) were female and the vast majority (94.3%)
presented at WHO stage 3 or 4. From the right-hand
size, 62 (4.1%) of the N* = 1,518 cohorts had an aver-
age age of ≤30 years, while 23 (1.5%) had an average
age >50 years. One hundred and fourteen cohorts
(7.5%) were all male and 135 (8.9%) were all female.
For the majority of cohorts (1,263; 83.2%) the preva-
lence of a WHO stage of 3/4 at registration was ≥90%.
Finally, 301 cohorts (19.8%) were at private clinics.Note, from the left-hand side of Table 3 these cohorts
accounted for 2,397 (2.9%) of the patients.
The overall six-month negative outcome rate was
19.5% (Table 1). The rate was highest among younger
and older patients, with patients aged 46–55 years
experiencing the lowest rate (17.6%). Furthermore, the
rate was lower among females (17.7% versus 22.2% for
males), among patients with WHO stage 1/2 (6.6%
versus 20.3% among patients with WHO stage 3/4) and
among patients registered at private clinics (12.6% versus
19.7% among patients at public clinics).
From the “gold-standard” analysis, presented in the
first column of Table 4, we see that patients at private
clinics have substantially lower adjusted odds of a
Table 4 Estimated odds ratios (OR) and 95% confidence intervals (CI) from logistic regression models for a negative















OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Agea
Linear 0.96 (0.94, 0.98) 0.35 (0.19, 0.66) 0.94 (0.25, 0.52) 0.94 (0.87, 1.01) 0.88 (0.80, 0.95)
Quadratic 1.06 (1.05, 1.07) 0.77 (0.54, 1.10) 1.05 (0.88, 1.00) 1.04 (0.99, 1.08) 1.03 (0.98, 1.08)
Gender
Male REF REF REF REF REF
Femaleb 0.72 (0.69, 0.74) 0.87 (0.82, 0.93) 0.75 (0.66, 0.84) 0.76 (0.67, 0.87) 0.71 (0.62, 0.82)
WHO stage
1/2 REF REF REF REF REF
3/4c 3.33 (2.97, 3.74) 1.57 (1.44, 1.72) 3.69 (2.62, 5.20) 3.31 (2.41, 4.55) 4.31 (2.87, 6.46)
Region
Central/North REF REF REF REF REF
South 0.92 (0.88, 0.95) 0.88 (0.82, 0.93) 0.93 (0.83, 1.05) 0.91 (0.80, 1.04) 1.02 (0.88, 1.17)
Year of registration
2005 REF REF REF REF REF
2006 0.91 (0.87, 0.95) 1.00 (0.94, 1.07) 0.97 (0.83, 1.05) 0.83 (0.68, 1.01) 0.88 (0.83, 0.93)
2007 0.76 (0.73, 0.80) 0.91 (0.85, 0.97) 0.74 (0.63, 0.86) 0.75 (0.62, 0.91) 0.75 (0.71, 0.80)
Clinic type
Public REF REF REF REF REF
Private 0.31 (0.20, 0.48) 1.08 (0.99, 1.19) 0.39 (0.13, 1.14) 0.31 (0.19, 0.50) 0.31 (0.20, 0.47)
Clinic/year interaction
Private/2006 2.16 (1.35, 3.46) 2.03 (0.95, 4.35) 2.20 (0.67, 7.28) 2.18 (1.30, 3.67) 2.20 (1.37, 3.53)
Private/2007 2.05 (1.26, 3.32) 1.98 (0.91, 4.32) 2.36 (0.69, 8.05) 2.07 (1.21, 3.52) 1.98 (1.22, 3.21)
aQuarterly-clinic cohort data model uses average age (in years).
bOR for the quarterly-clinic cohort data model corresponds to a contrast of 20% in the percent female.
cCovariate in the quarterly-clinic cohort data model is a binary indicator of whether or not the the percent WHO stage 3/4 is ≤/> 90%.
dSee Table 2 for details; Design #1 stratifies on clinic type; Design #2 stratifies on clinic type and year of registration.
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negative outcome for a patient registered at a private
clinic in 2005 are estimated to be 69% lower than the
odds of a patient registered at a public clinic in 2005
(OR 0.31; 95% CI 0.20, 0.48). Furthermore, the interaction
terms are statistically significant (overall p-value < 0.01).
Combining the main effect and interaction terms, the
year-specific private/clinic ORs in 2006 and 2007 are 0.67
(95% CI 0.56, 0.79) and 0.63 (0.52, 0.77), respectively, indi-
cating that while the gap between private and public
clinics diminished from 2005 to 2006, it did not diminish
completely and remained constant through 2007.
The second column of Table 4 provides results based
on the group-level analysis of the quarterly-clinic cohort
data. Comparing with the first column, we see discrep-
ant results between the patient- and group-level analyses
for the effects of age, gender and WHO stage. For
gender and WHO stage, the point estimates based onthe aggregated data analysis are substantially attenuated,
although remain statistically significant. Analyses based
on patient-level data indicate a statistically significant
U-shaped relationship between age and six-month out-
comes (see Figure 1). Analyses based on group-level
data fail to identify a statistically significant quadratic
term and erroneously suggest a linear effect for age.
This is a classic manifestation of ecological bias.
The third column of Table 4 provides results based on
a single case–control draw of n = 5,000 patients from
the N = 82,877 available in the survey. Overall the results
based on the case–control data and the gold-standard
analyses are consistent with each other, despite the
former only requiring detailed data on a fraction (5,000
of 82,877; 6%) of the patient records. The fourth and
fifth columns of Table 4 provide results based on a sin-
gle phase II draw under Designs #1 and #2. As with the

















































Figure 1 Results on the association between age and negative outcome status based on the complete patient data (N = 82,877 patient
records) and the quarterly-clinic cohort data (N* = 1,518 records). Shown are odds ratio estimates and 95% confidence intervals; the referent
age level for the odds ratio associations is 45 years.
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One crucial difference, however, is that the confidence
intervals for the clinic effect are much tighter under the
two two-phase designs; compare (0.13, 1.14) to (0.19,
0.50) and (0.20, 0.47). Indeed, the results/conclusions for
clinic type based on the two-phase designs are almost
equivalent to those based on the gold standard even
though the former uses a fraction (again, 5,000/82,877;
6%) of the patient data. Similarly, compared to the case–
control design, the estimates/conclusions for the two
interaction terms are substantially improved under
either of the two-phase designs.
Figure 2 provides the results from the simulation
study. The grey line indicates that analyses based on the
complete data (i.e. N = 82,877) had approximately 90%
power to detect the clinic/year interaction. From the
Figure we see that a case–control design with n = 10,000
patients would only have approximately 23% power.
Increasing the case–control sample size to n = 20,000
only increases power to 53%; at n = 40,000, power is
approximately 80%. In comparison, one would only need
n = 5,000 phase II samples under two-phase Design #1
to have approximately 80% power. Under Design #2, a
phase II sample size as low as n = 500 would provide
more than 85% power to detect the clinic/year interaction.
Furthermore, when the phase II sample size is n = 2,000,
Design #2 has equivalent statistical power to a study in
which patient-level data was collected on all N = 82,877
patients.Discussion
Given significant financial constraints, effective and
comprehensive monitoring remains a critical challenge
for many national ART programs. There is therefore a
pressing need for innovative strategies that are robust to
ecological bias and that permit M&E of patient-level
outcomes and their associations with risk factors. The
two-phase study design is one such strategy, providing a
cost-efficient approach to combining and making best
use of two sources of information: the existing aggre-
gated group-level counts and the sub-samples of patient-
level data. Using relatively recent advances in statistical
methodology, the designs are flexible and can often per-
mit the investigation of patient-level outcomes/associa-
tions with detailed information on only a fraction of
patient registrants. This core feature provides important
flexibility for resource-limited settings where minimizing
costs is a major concern.
The example used to illustrate the two-phase design
considered a very specific question: the relationship
between clinic type (public/private) and outcomes, and
whether or not the relationship varied over time. In
general, stratification improves power for detecting ef-
fects association with the stratification variables. This
manifested in our example through the enormous im-
provements in power when the phase I stratification
was based on clinic type and year of registration. There
is, however, a trade-off, in that statistical power can be
reduced for effects associated variables that are not


















Two−phase #2: clinic type and year
Two−phase #1: clinic type
Case−control study
Figure 2 Estimated post-hoc power to detect an interaction between clinic type and year of registration under (i) a gold-standard
complete data design with patient-level data on all N = 82,877 patients; (ii) a case–control design; (iii) a two-phase design, stratifying
on clinic type; and, a two-phase design, stratifying on clinic type and year of registration.
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in the analyses of Table 4 where standard error esti-
mates for the age, WHO stage and region coefficients
are all approximately 20% bigger under the two-phase
designs than the case–control design. This highlights
the importance of careful study design when choosing
the phase I stratification scheme and gearing it to the
goals of the study. It also highlights the important
distinction between one-time studies of some specific
question, such as the one considered in this paper, and
more general on-going M&E efforts. For the latter, in
which data from sub-samples of patients may be rou-
tinely collected the choice of phase I stratification will
need to be tailored to more general sets of goals. How
this is done remains an open question and represents
an important avenue for future research.
The overarching goal of this paper is to emphasize the
value added to aggregate program data with the use of a
two-phase design. Beyond the two-phase design, the
survey sampling literature provides a broad range of
strategies for collecting individual-level data [36,37].
One could, for example, perform clustered sampling in
which a random sample of clinics is chosen and then a
random sample of patients within each clinic is identified.
Such an approach is useful from a logistical perspective
since individual-level data need only be collected from a
limited number of clinics. One benefit of the two-phase
design in the Malawian context, however, is the flexible,
explicit use of the aggregated data via the design (i.e. phase
I stratification) and the recently developed efficient ana-
lyses techniques [25,26].The data used for this illustrative purpose had several
limitations in terms of missing data and limited data
fields, and may suffer from additional data quality issues
that are common in the field (e.g. misclassification and
measurement error). The results themselves are illustra-
tive only and are not intended to be generalizable to
either the Malawian national ART program or beyond.
Further, while there are discrepancies in results based on
the patient-level data compared to the aggregated data-
sets, the intention of this paper is not to undermine the
critical role of the aggregated program data. Certainly
there is precedence in the use of this aggregated data to
monitor patient outcomes, forecast program need, and
make statements about the utility of national treatment
programs. Crucially, it is when aggregated data are used
to to make statements about more complex relationships
between exposures and outcomes that bias and the eco-
logical fallacy can arise. Whether or not the underlying
quality of the aggregated data impacts the efficiency
gains of a two-phase study is an open design question
and one we are actively pursuing.
Throughout, we have sought to emphasize the practical
utility of two-phase designs in making efficient use of in-
formation that already exists (i.e. the information already
collected by the Malawian national ART program). The
statistical literature laying out the theoretical foundation
for these designs is rich, with much of the development in
the last 20 years [25-27,34,38], In the context of this paper,
as pointed out by a reviewer, program registrants are clus-
tered within clinics and, as such, a complete data analysis
would require acknowledging this phenomenon to ensure
Haneuse et al. BMC Medical Research Methodology  (2015) 15:31 Page 9 of 10valid inference. Interestingly, the literature on two-phase
designs focuses exclusively on settings where individual
study units are independent; that is, the context where
study units are cluster-correlated has not been considered
for two-phase designs. Indeed, to our knowledge, no
statistical methods have been published for data arising
from a standard case–control design when the under-
lying patient population exhibits clustering. As such, we
have not considered the potential effects of clustering.
With respect to the key messages of this paper, however,
such clustering does not impact the notion that
individual-level data can be used to alleviate ecological
bias and it is unlikely to impact the relative differences
in statistical efficiency/power between the case–control
and two-phase design. Towards the latter, we are
actively developing methods for cluster-correlated case–
control and two-phase designs, as well as case–control
designs where a fixed number of cases and controls are
selected from each clinic [39].
Finally, while this work is motivated by challenges
posed to the Malawian national ART program, the ap-
proach will be useful in a wide array of resource-limited
settings both, at the national and local scale. In particu-
lar, the availability of this strategy could help inform de-
cisions on monitoring efforts faced by (i) other programs
that currently use aggregated data for monitoring, (ii)
programs that collect patient-level data but where cer-
tain data elements are either missing or subject to meas-
urement error; and, (iii) programs that currently collect
comprehensive patient-level data but are interested in
strategies to reducing costs.Conclusions
Currently, ART programs in resource-limited settings
rely on aggregated facility-level data to perform M&E
and are therefore subject to potential ecological bias.
Two-phase designs provide a flexible framework for ju-
diciously collecting sub-samples of patient-level data.
Specifically, by making use of existing data collection
efforts to form efficient sampling frames, the two-
phase design permits the resolution of ecological bias,
giving researchers the ability to address a broad range
of patient-level questions. Furthermore, the design is
cost-efficient in the sense that, when compared to
standard designs such as the case–control study, far
fewer patients need to be sampled to achieve a desired
level of statistical efficiency and power.
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